ETODOLAC Drug Patent Profile
✉ Email this page to a colleague
When do Etodolac patents expire, and when can generic versions of Etodolac launch?
Etodolac is a drug marketed by Ani Pharms, Apotex, Biopharm, Chartwell Molecules, Mylan, Sandoz, Taro, Actavis Elizabeth, Bayshore Pharms Llc, Teva, Watson Labs Florida, Zydus Pharms, Amneal Pharms Co, Apotex Inc, Edenbridge Pharms, Ivax Sub Teva Pharms, Oxford Pharms, Ranbaxy Labs Ltd, Shree Hari Intl, Taro Pharm Inds, and Watson Labs. and is included in thirty-seven NDAs.
The generic ingredient in ETODOLAC is etodolac. There are twenty-three drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the etodolac profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Etodolac
A generic version of ETODOLAC was approved as etodolac by SANDOZ on April 11th, 1997.
Summary for ETODOLAC
Recent Clinical Trials for ETODOLAC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Kutahya Health Sciences University | Phase 4 |
Memorial Sloan Kettering Cancer Center | N/A |
Apsen Farmaceutica S.A. | Phase 3 |
Pharmacology for ETODOLAC
Drug Class | Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors |